TY  - CHAP
M1  - Book, Section
TI  - Endovenous Laser Ablation
A1  - Weiss, Robert A.
A1  - Weiss, Margaret A.
A1  - Beasley, Karen L.
Y1  - 2012
N1  - 
T2  - Sclerotherapy and Vein Treatment, 2e
AB  - When  saphenous  system  reflux  is  present,  it  must  be  addressed  prior  to  treatment  of  visible  and  associated  varicosities,  reticular  veins,  or  telangiectasias.  Endovenous  occlusion  techniques  using  radiofrequency  (RF)  or  laser  have  become  the  standard  of  care  in  the  United  States.  When  using  laser,  they  are  termed  ELT  or  ELA,  which  are  abbreviations  for  endovenous  laser  therapy  or  treatment  or  endovenous  laser  ablation,  respectively.  Without  elimination  of  reflux,  the  patient  will  be  doomed  to  recurrence  after  recurrence  of  varicosities  below  the  level  of  saphenous  vein  reflux.  Previously,  the  only  treatment  option  for  these  patients  with  varicose  veins  from  saphenous  insufficiency  was  surgical  ligation  and  stripping  of  the  vessels  under  general  anesthesia.  This  procedure  resulted  in  significant  postoperative  down  time,  with  surgical  scars,  swelling,  bruising,  and  pain.  The  expense  of  a  hospital  stay  and  missed  work,  along  with  an  unacceptable  rate  of  recurrence,  has  greatly  decreased  the  popularity  of  this  procedure  and  relegated  it  to  low  technology  medical  arenas  (see  Chapter  23).  Like  many  other  fields  of  medicine,  varicose  vein  treatment  in  the  21st  century  has  evolved  and  adopted  less-invasive  methods.  RF  ablation  started  the  minimally  invasive  varicose  vein  trend  with  approval  in  March  1999  by  the  U.S.  Food  and  Drug  Administration  (FDA)  as  the  Closure®  procedure  (VNUS  Medical  Technologies,  San  Jose,  CA).  Endovenous  ablation  techniques  utilizing  lasers  were  subsequently  filed  as  U.S.  FDA  510(k)  applications  as  substantially  equivalent  procedures  to  RF  ablation.  The  first  laser  FDA  cleared  by  substantial  equivalence  to  RF  was  the  810-nm  diode  laser,  which  was  cleared  for  marketing  in  2000.  
SN  - 
PB  - McGraw Hill LLC
CY  - New York, NY
Y2  - 2024/04/16
UR  - dermatology.mhmedical.com/content.aspx?aid=1175621422
ER  -